


PRODUCT INFORMATION



GW 9508

Item No. 10008907

CAS Registry No.: 885101-89-3
Formal Name: 4-[[[3-phenoxyphenyl)methyl]amino]-benzenepropanoic acid
MF: C₂₂H₂₁NO₃
FW: 347.4
Purity: ≥98%
UV/Vis.: λ_{max}: 245, 297 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GW 9508 is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 9508 in an organic solvent purged with an inert gas. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of GW 9508 in these solvents is approximately 15 mg/ml.

GW 9508 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GW 9508 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. GW 9508 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GW 9508 is a small-molecule agonist of GPR40/FFA1 (EC₅₀ = 47.8 nM for calcium mobilization in HEK293 cells).¹ It is selective for GPR40/FFA1 over GPR120/FFA4 (EC₅₀ = 3,467 nM), as well as GPR43/FFA2 and GPR41/FFA3 (EC₅₀s = >50 μM).¹ GW 9508 potentiates glucose-stimulated and potassium chloride-mediated insulin secretion in MIN6 pancreatic β-cells but does not affect glucose-stimulated insulin secretion in primary rat or mouse islet cells.¹ It increases phosphorylation of AMP-activated protein kinase (AMPK) and acyl-CoA carboxylase (ACC), indicating AMPK and ACC activation, and decreases hepatic lipid accumulation in a mouse model of high-cholesterol diet-induced hepatic steatosis when administered at a dose of 100 mg/kg per day for three days.²

References

1. Briscoe, C.P., Peat, A.J., McKeown, S.C., *et al.* Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules. *Br. J. Pharmacol.* **148(5)**, 619-628 (2006).
2. Li, M., Meng, X., Xu, J., *et al.* GPR40 agonist ameliorates liver X receptor-induced lipid accumulation in liver by activating AMPK pathway. *Sci. Rep.* **6:25237**, (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/24/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM